GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. 11:35:12 2024-09-18 EDT 5-day change 1st Jan Change
1,604.00 GBX -0.34% Intraday chart for GSK plc -3.05% +10.61%
LockCet article Alphavalue, leader européen de la recherche indépendante, est réservé aux abonnés
Alphavalue est en exclusivité chez Zonebourse.
Pour débloquer l'article, ABONNEZ-VOUS !
Vous êtes déja client ? Log In
European Equities Close Lower in Wednesday Trading; EU, Euro Area Inflation Declines in August MT
GSK Settles Two California Lawsuits Related to Zantac MT
GSK: two Zantac-related claims settled out of court CF
Britain's GSK Reaches Settlements for Two US Lawsuits MT
GSK settles two California lawsuits related to heartburn drug Zantac RE
GSK reaches further two settlements regarding Zantac AN
GSK : Jefferies reaffirms its Buy rating ZD
GSK Says Trial Evaluating Co-Administration of AREXVY, SHINGRIX Shows Non-Inferior Immune Response MT
GSK Sees Positive Results in Trial of Combination RSV, Shingles Vaccine DJ
GSK plc Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX CI
IDEAYA Biosciences, Inc. Appoints Douglas B. Snyder as Senior Vice President, General Counsel CI
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading MT
GSK: Japan agrees to review Blenrep application CF
GSK : JP Morgan remains a Sell rating ZD
GSK says Blenrep combinations accepted for review in Japan AN
GSK's Blood Cancer Treatment Application Accepted for Review in Japan MT
GSK PLC : Despite transitioning towards speciality pharma, GSK is trading at OTC prices Alphavalue
ITeos Therapeutics Shares Rise on Positive Data From Lung Cancer Study DJ
GSK : Goldman Sachs gives a Neutral rating ZD
Moderna's Faces 'Material Headwinds' on RSV, COVID, RBC Says MT
GSK Bets on Blood-Cancer Drug Comeback Amid Oncology Push DJ
European Equities Close Higher on Friday; HSBC Mulls Potential Sale of South African Unit MT
GSK Says Blenrep Granted Breakthrough Therapy Designation in China MT
GSK: innovative therapy designation granted in China CF
GSK : Goldman Sachs reaffirms its Neutral rating ZD
Chart GSK plc
More charts
Logo GSK plc
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.
Employees
70,212
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
16.04GBP
Average target price
19.22GBP
Spread / Average Target
+19.82%
Consensus
  1. Stock Market
  2. Equities
  3. GSK Stock
  4. News GSK plc
  5. GSK plc: Vaccines’ disappointment overshadows the Q2 beat and the guidance upgrade
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW